Hyperlipidemia Therapeutics - Pipeline Analysis 2018

Hyperlipidemia Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments

Published: January 2018
Report Code: LS11140
Available Format:
Pages: 173

Note: This report can also be updated as of date and delivered within 1-2 workings days of purchase confirmation

Hyperlipidemia refers to the condition of elevated amount of lipids and cholesterol in the bloodstream. The two major types of lipid abnormalities are characterized by either high blood levels of triglycerides (known as hypertriglyceridemia) or high blood cholesterol levels (known as hypercholesterolemia).




Hyperlipidemia is often associated with increased risk of coronary heart disease and strokes. Risk factors for hyperlipidemia include obesity, physical inactivity and improper diet with saturated fat content. Disease conditions such as hypothyroidism, diabetes mellitus, liver disease, kidney disease, certain medications, as well as alcoholism can elevate lipid levels. Also, family history of high cholesterol put a person at high risk for hyperlipidemia.

An increase in number of cases of patients with hyperlipidemia is anticipated in coming years due to unhealthy lifestyle. Several factors that increase the risk of hyperlipidemia include unhygienic diet intake with high amount of trans fat, lack of physical activity, obesity, and smoking. Other factors include stress, high blood pressure, type II diabetes mellitus, and thyroid disorders.

Also, with advancements in technology, many pharmaceutical companies are leveraging new and improved technologies for the development of drug candidates to treat hyperlipidemia. These technologies are helpful in the development of drugs as either combination therapies or single-agent therapies. They also allow the development of specific targeted therapies with effective drug delivery. Thus, the above factors contribute towards the hyperlipidemia pipeline growth.

Pipeline Analysis

As of January 2018, the hyperlipidemia therapeutics pipeline comprises of 53 drug candidates in different stages of development.

Competitive Landscape

Some of the key players involved in the development of hyperlipidemia therapeutics include Novartis AG, Eli Lilly and Company and Merck & Co. Inc.

Place An Order

Single User License

The report will be delivered in PDF format without printing rights. It is recommended for a single user.

USD 2500
Group License

The report will be delivered in PDF format along with the printing rights. It is recommended for up to five users.

USD 3250
Enterprise License

The report will be delivered in PDF format along with printing rights and detailed Excel sheet. It is recommended for organizations where multiple people would like to access the report from multiple locations.

USD 7750

Pre-Purchase Enquiry